In Vitro Control of Genes Critical for Parathyroid Embryogenesis by Extracellular Calcium by Fabbri, Sergio et al.
July 2020 | Vol. 4, Iss. 7
doi: 10.1210/jendso/bvaa058 | Journal of the Endocrine Society | 1–13
ISSN 2472-1972
Received 11 February 2020
Accepted 22 May 2020
First Published Online 25 May 2020
Corrected and Typeset 30 June 2020
In Vitro Control of Genes Critical 
for Parathyroid Embryogenesis by 
Extracellular Calcium
Sergio Fabbri,1 Roberto Zonefrati,1 Gianna Galli,1 Giorgio Gronchi,3 Giuliano Perigli,2 
Andrea Borrelli,4 and Maria Luisa Brandi1
1Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; 
2Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 3Department of 
Neuroscience, Psychology, Drug Research & Child Health, University of Florence, Florence, Italy; and 4Bariatric, 
General Surgery and Metabolic Department, Santa Maria Nuova Hospital, Florence, Italy
ORCiD numbers: 0000-0002-8741-0592 (M. L. Brandi).
  
Background: The expression of the parathyroid transcription factors, encoded by the genes GATA3, 
GCM2, and MAFB, persists after parathyroid morphogenesis. This suggests a role of these genes in 
the regulatory program that governs parathyroid function in the adult. Indeed, these 3 genes form a 
transcriptional cascade able to activate PTH gene expression.
Materials and Methods: Adult adenoma parathyroid tissues were put in primary cell culture to 
evaluate the messenger ribonucleic acid (mRNA) expression of the PTH gene, of the genes involved 
in the calcium regulatory signaling pathway (CaSR, GNA11, and AP2S1), and of the 3 genes (GATA3, 
GCM2, and MAFB) involved in the parathyroid morphogenesis in the presence of different extracel-
lular calcium concentrations from 0.1 mM to 3.0 mM.
Aim: The aim of the study was to investigate whether different extracellular calcium conditions could 
control the expression of transcription factors critical for parathyroid embryogenesis.
Results: The results of the experiments showed that the mRNA expression of GATA3, GCM2, and 
MAFB genes follows the same response as the PTH gene to extracellular calcium concentrations, with 
the highest expression at low calcium (0.1 mM) and the lowest at high calcium (3.0 mM). Conversely, 
the genes involved in the calcium signaling in the parathyroid cells showed a variable response to the 
extracellular calcium concentrations, with the CaSR and GNA11 genes exhibiting a sensitivity to low 
calcium concentrations.
Conclusions: These findings indicate that transcription factors recognized for their role in parathy-
roid embryogenesis show a response to extracellular calcium later in adulthood that parallels the 
behavior of the PTH gene.
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Parathyroid glands serve a pivotal function in the regulation of calcium and phosphate ho-
meostasis by secreting parathyroid hormone (PTH), which controls the serum calcium con-
centration through the increase of calcium absorption from bone and calcium reabsorption 
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in the kidney. Parathyroid chief cells, the most abundant cells of these glands, are able to 
detect small changes in blood ionized calcium levels, modifying PTH release via a calcium-
sensing receptor (CaSR) [1].
The discovery that transcription factors active in the embryogenesis of the parathyroid 
glands were also expressed postnatally in the parathyroid tissue prompted investigation 
of their role in adult parathyroid physiology [2]. The transcription factors essential for 
the development of the parathyroid glands—GATA binding protein 3 (GATA3), glial cells 
missing 2 (GCM2), and transcriptional activator v-maf muscoloaponeurotic fibrosarcoma 
oncogene homologue B (MAFB) appear all to be part of a genetic cascade capable of directly 
regulating PTH gene expression. Indeed, in the rodent model the complex of the three par-
athyroid morphogenesis genes controls Pth gene expression through the stimulation of its 
promoter in a hierarchic sequence, where Gata3 is the gene activated more upstream and 
MafB is activated the more downstream, with Gcm2 acting in the middle [3,4].
Gata3 knockout mouse embryos lack Gcm2 expression and have defects in the third and 
fourth pharyngeal pouches, including absent parathyroid-thymus primordia [5]. Gata3 
transactivates the Gcm2 gene by binding specifically to a double-GATA-motif within the 
Gcm2 promoter. In addition, Gata3 cooperates with Gcm2 and MafB to activate the Pth 
gene expression with the ubiquitous specific protein 1 transcription factor [6].
GATA3 gene (OMIM# 146255) sits in chromosome 10p14 in humans. Its encoded product 
was shown to have an important role in embryogenesis, development, and cell differenti-
ation, not only in the parathyroid glands and the thymus, but also in several other organs 
and tissues, including kidney, breast, nervous system, lymphocytes, and hair follicles [7-
9]. Haploinsufficiency of the GATA3 gene, caused by various types of mutations, including 
point mutations as well as small- and large-scale deletional mutations, cause a very rare 
autosomal dominant genetic hypoparathyroidism deafness renal dysplasia syndrome with 
the triad of affected organs variably manifested in affected patients [10]. The GATA3 gene 
is located in a site on chromosome 10p13/14 where the critical DiGeorge region II is sitting 
and terminal deletions (10p14-10pter) are linked to the hypoparathyroidism deafness renal 
syndrome, whereas interstitial deletions in the 10p13-14 site are linked to the DiGeorge 
phenotype [11]. Moreover, the GATA3 gene is expressed in adult parathyroid cells and can 
be used as a specific immunohistochemical biomarker for cells of parathyroid origin [12,13].
In Drosophila, the zinc-finger type transcription factor glial cell missing (GCM) acts as a 
developmental binary switch between glia and neurons. In mammals, there are 2 orthotics, 
GCM1/GCMA and GCM2/GCMB, linked respectively to placental and parathyroid development 
[3]. In Gcm2-null mice, parathyroid precursor cells die of apoptosis, and terrestrial vertebrates 
missing the parathyroid glands develop hypocalcemia and hyperphosphatemia, as observed in 
hypoparathyroidism, and die soon after birth [5,14]. In humans, the 5 exons of the GCM2 gene 
(OMIM# 603716) on chromosome 6p24.2 encode a protein of 506 amino acids, and inactivating 
mutations in the gene were causal of hypoparathyroidism in kindreds affected by autosomal 
recessive or dominant disease [15,16]. The gene continues to be expressed in the adult [3], and 
its role in parathyroid physiology was investigated. Using rat parathyroid cells in culture [17] 
Kawahara et al showed that Gcm2 binds to the PTH gene 5’ promoter to regulate its transcrip-
tion [18]. A series of analyses indicate that GCM2 subsequently controls serum calcium concen-
tration by modulating CaSR gene expression and promoting PTH secretion [19]. The absence or 
reduction of GCM2 transcription factor, both in vivo in mice and in human parathyroid cultured 
cells treated with GCM2 gene siRNA, correlates with lack of or decreased expression of the 
CaSR gene, a marker of differentiation for the parathyroid cells [19].
v-MAF muscolo-aponeurotic fibrosarcoma oncogene homologous B (MAFB), is a transcription 
factor member of the MAF family, characterized by a basic leucine zipper region, affecting tran-
scription positively or negatively, depending on its partner proteins [20]. MAFB plays impor-
tant roles in the developmental processes of various tissues, as well as in cell‐type‐specific gene 
expression, by binding directly to MAF‐recognition element–related sequences either in their 
promoter or enhancer regions. MafB gene knockout in mice has shown that its encoded protein 
regulates respiratory rhythmogenesis in the brain [21], monocyte and osteoclast differentiation 
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[22,23], and maturation of pancreatic islet α and β cells [24]. MAFB also stimulates the expres-
sion of tissue‐specific genes such as F4/80 in macrophages, glucagon, and insulin in pancreatic 
islets [25,26]. MAFB is essential for the later steps of parathyroid development, which involve 
the separation from the thymus and the migration toward the thyroid gland. MafB expression 
persists after morphogenesis and in adult parathyroid glands [27]. MAFB and GCM2 interact 
with each other, binding directly to an evolutionally conserved region of the PTH gene pro-
moter, and synergistically activate its transcription [28]. In recent studies, Maf heterozygote 
(Maf+/-) or knockout (Maf-/-) mice with induced secondary hyperparathyroidism do not develop 
an increased secretion of Pth, nor an enlargement of the parathyroid glands through a reduc-
tion of Pth and Ccnd1 (cyclin D1) genes expression [4]. These findings suggest that MAFB may 
represent a new therapeutic target in secondary hyperparathyroidism. In humans, MAFB gene 
(OMIM# 608968) localizes on chromosome 20q12.2-q13.1, and mutations of the gene have been 
correlated with multicenter carpotarsal osteolysis [29] and Duane retraction syndrome 3, with 
or without deafness [30].
Besides the effect on PTH gene expression, neither the role of these transcription factors on 
parathyroid cell development and function nor the regulation of their expression in the para-
thyroid tissue is fully understood. The functional machinery that controls parathyroid phys-
iology encompasses extracellular ionized calcium, CaSR, guanine nucleotide-binding protein 
subunit alpha-11 (GNA11), adaptor related protein complex 2 subunit sigma 1 (AP2S1), and 
PTH. The CaSR, a guanine nucleoside-binding protein (G-protein-coupled receptor [GPCR]), is 
abundant in the parathyroid glands and in the kidneys, where it is pivotal in the regulation of 
PTH secretion and in the renal excretion of calcium. Loss-of-function mutations in the CaSR 
gene lead to 3 hypercalcemic disorders: familial hypocalciuric hypercalcemia type 1, neonatal 
severe hyperparathyroidism, and primary hyperparathyroidism (PHPT) [31,32]. Conversely, 
the activating mutations of this gene cause a hypocalcemic disorder, known as autosomal dom-
inant hypocalcemia syndrome [33]. The GNA11 gene encodes for the subunit α11 in the tri-
meric G-protein and mediates the signaling of GPCRs, and the AP2S1 gene encodes for the 
adaptor protein-2 σ subunit, which plays a role in the internalization of membrane proteins, 
including GPCRs [34]. Inactivating mutations of GNA11 and AP2S1 genes are responsible, re-
spectively, for familial hypocalciuric hypercalcemia type 2 and type 3 [35].
In this study, for the first time, the expression of transcriptional factors GATA3, GCM2, 
and MAFB was evaluated in a human model of primary cultures of parathyroid adenomatous 
cells, along with the expression of the functional genes CaSR, GNA11, AP2S1, and PTH, 
under low, normal, and high extracellular calcium concentrations.
Materials and Methods
Sample acquisition
Fresh parathyroid adenoma tissue was obtained during parathyroidectomy for PHPT at 
Careggi and Santa Maria Nuova hospitals in Florence, Italy, between April 2018 and July 
2019. Eight parathyroid tissues from 8 patients, were collected during this time period.
All patients with PHPT, sporadic and nonsyndromic, had a single parathyroid adenoma. 
PHPT was diagnosed based on serum calcium and intact PTH levels in the absence of other 
possible causes of hypercalcemia (Table 1). Of the 8 PHPT patients, 4 were male and 4 fe-
male, with a mean age of 66 ± 12. The mean size of a parathyroid adenoma was 2.2 ± 0.5 × 
1.5 ± 0.5 cm. This study was approved by the Regional Ethics Committee for Clinical Trials 
of the Tuscany Region (12599_bio, April 2018).
Cell Cultures
Knife biopsies of the waste tissues obtained from surgery were immediately placed in 
McCoy’s 5A medium (Sigma Aldrich, St Louis, MO, US) supplemented with sterile 22 mM 
HEPES (Sigma Aldrich), 100 IU/mL penicillin, and 100  µg/mL streptomycin, pH 7.4, 
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transported to the laboratory, and processed within 30 min from excision. The parathyroid 
tissues were trimmed of extraneous fatty tissue and its capsule of fibrous connective, sliced 
into ~ 0.2 to 0.5 mm thickness with a knife, and placed into collagenase type I 0.3 mg/ml 
(C-0130; Sigma Aldrich) in Coon’s modified Ham’s F-12 medium supplemented with fetal 
bovine serum (FBS) 20%, 100 IU/mL penicillin, 100 µg/mL streptomycin, overnight at 37°C 
in humidified air with 5% CO2. The following day, once the collagenase was removed by 
washing 3 times with serum-free medium, the cells were mechanically dispersed by vigorous 
pipetting through 10 mL pipettes. The digested tissues were then incubated in 100 mm cul-
ture dishes in Coon’s modified Ham’s F-12 medium (1.12 mM calcium) supplemented FBS 
10% (0.1 mM calcium), 100 IU/mL penicillin, 100 µg/mL streptomycin, incubated at 37°C in 
humidified air with 5% CO2. After 24 h, once parathyroid cells were attached to the plate, 
they were detached with trypsin 0.4 mg/mL, collected, and transferred into 48-multiwell 
plates in Coon’s modified Ham’s F-12 medium, with FBS 10%, 100 IU/mL penicillin, 100 µg/
mL streptomycin, incubated at 37°C in humidified air with 5% CO2. After another 4 days, 
the medium was replaced with Dulbecco’s modified eagle’s medium (DMEM) and Ham’s 
F-12 Nutrient Mixture (Sigma Aldrich), calcium-free medium, with 3 different calcium 
concentrations added for 1 h (0.1 mM, 1.2 mM, and 3.0 mM).
Immunofluorescence staining
The intracellular PTH and the CaSR proteins were evaluated with immunofluorescence 
staining in adenoma parathyroid cells after 5 days in culture in growth Ham’s F12 Coon’s 
modified medium with an addition of 10% FBS. The cells were then transferred into glass 
slides an incubated in DMEM medium containing 1.2 mM calcium and after 24 h fixed in 4% 
paraformaldehyde in Dulbecco’s phosphate-buffered saline (DPBS) for 20 min at room tem-
perature and permeabilized in 0.5% Triton X-100 in DPBS for 10 min at room temperature. 
Nonspecific binding sites were blocked with 2% bovine serum albumin (BSA) in DPBS for 
30 min at room temperature. The staining for the PTH was done using an anti-PTH (mon-
oclonal rabbit, SAB5500159, Sigma-Aldrich, MO, US) [36] primary antibody 1:100 in 2% 
BSA/DPBS for 4 h at room temperature in a humidified chamber and a fluorescein isothi-
ocyanate conjugated anti-rabbit immunoglobulin G goat host (F0382, Sigma-Aldrich, MO, 
US) [37] secondary antibody 1:100 in 2% BSA/DPBS for 60 min in the dark at room temper-
ature in humidified chamber. The staining for the CaSR was done using 1:100 anti-CaSR 
(monoclonal anti-human, MA1-934, clone 5C10, ADD, Thermo Fisher Scientific, Waltham, 
MA, US) [38] primary antibody in 2% BSA/DPBS overnight at 4°C. Revelation was obtained 
using 1:50 fluorescein isothiocyanate-rabbit anti-mouse immunoglobulin G secondary an-
tibody (SA1-10651, Thermo Fisher Scientific, Waltham, MA, US) [39] in 2% BSA/DPBS for 
60 min at room temperature. Cell nuclei were counterstained with 10-5M propidium iodide 
(Invitrogen, Carlsbad, CA, US) for 30 min in the dark at room temperature in a humidified 
chamber after RNA digestion with 500 µg/ml RNase I-A (Sigma-Aldrich, St. Louis, MO, US) 
for 30 min at room temperature. Samples were rinsed 3 times with 2% BSA/DPBS between 
Table 1. Pre-operative calcium (normal reference serum range 8.5-10.5 mg/dL) and PTH (normal ref-
erence serum range 10–77 pg/mL) levels of the parathyroid adenomas
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each step. Cells were observed in laser scanning confocal microscopy using a LSM510META 
microscope equipped with Ar/ML458/477/488/514, HeNe543, HeNe633 laser lines (ZEISS, 
Oberkochen, Germany).
Messenger ribonucleic acid collection, reverse transcription, and gene expression
Cultured cells were then washed with phosphate-buffered saline (PBS), mixed with a lysis 
solution, containing reagents to inactivate endogenous RNAases, also added with DNAase 
I, and incubated at room temperature for 5 min. Cells were lysed during this incubation 
and RNA released into the lysis solution. A stop solution was then added to inactivate the 
lysis. Cell lysates were reverse transcribed to synthesize complementary deoxyribonucleic 
acid using a 20× enzyme mix and a 2× reverse transcription buffer. Finally, the complemen-
tary deoxyribonucleic acid was amplified by real time polymerase chain reaction (RT-PCR) 
using a Taqman® Gene Expression Master Mix (TaqMan® Gene Expression Cells-to-CT 
TM 
Kit, Thermo Fisher). The genes amplified were actin beta (ACTB) as housekeeping gene 
and PTH, CaSR, GATA3, GCM2, MAFB, GNA11, and AP2S1 with Rotor-Gene System 
(Qiagen®).
Taqman primers and probes
Primers and probes (IDT DNA Technologies®) for comparative RT-PCR (Rotor-Gene Q 
Software) with calibrator conditions fixed in 1.2 mM calcium, were reported in Table 2. The 
RT-PCRs were conducted in triplicate according to the manufacturer’s protocol (Taqman® 
Gene Expression Cells-to-CT 
TM Kit, Thermo Fisher).
Statistics
Descriptive statistics (mean and standard deviation) related to the expression of each 
gene (PTH, GATA3, GCM2, MAFB, CASR, GNA11, and AP2S1), in different calcium 
concentrations, were analyzed for each parathyroid. Statistical significance of the differences 
between means was evaluated through a mixed model approach, taking into account the 3 
levels of calcium in the medium (0.1, 1.2, and 3.0 mM) as fixed factor. Random factors were 
the triplicates and the different parathyroids. For each test omnibus, Bonferroni-corrected 
post-hoc tests were conducted. Experiment-wise alpha-level was α t = 0.05. The statistical 
analyses were performed using R software.
Results
Phase contrast microscopy observations showed a characteristic morphology of in vitro-
grown parathyroid glandular parenchyma (Fig. 1A), and immunocytochemistry confirmed 
the presence of the CaSR and PTH proteins in the presence of 1.2 mM calcium (Fig. 1B 
and C).
The 8 parathyroid cell primary cultures obtained were evaluated for in vitro calcium 
responsiveness.
Table  3 reports the results of descriptive statistics related to single parathyroid 
preparations. With regard to PTH, the 8 parathyroids had a higher value at 0.1 mM calcium 
compared to 1.2 mM and to 3.0 mM. Together with the PTH, all the transcription factors 
analyzed, GATA3, GCM2, and MAFB, demonstrated the same tendency in the response to 
extracellular calcium concentration in the majority of the parathyroids tested. With regard 
to the CaSR and GNA11, the majority of the parathyroid preparations showed the same 
tendency when comparing 0.1 mM to 1.2 mM, with a higher value in the lower calcium 
conditions and an increase in the expression at 3 mM calcium.
These trends were confirmed at an inferential level considering the mean values of each 
condition. With regard to the PTH, the mean values were different with respect to the 
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different levels of calcium (0.1 mM low, 1.2 mM physiological, 3.0 mM high) (F(2,179) = 5.39, 
P = 0.0053), with the mean value observed at 0.1 mM calcium being significantly higher than 
the value at 1.2 mM (t = −2.84, P = 0.0051) and the value at 3.0 mM (t = −2.95, P = 0.0036). 
As expected, the PTH gene expression was modulated in vitro with an inversely propor-
tional tendency to extracellular calcium concentrations (Fig. 2A).
The GATA3 gene expression was influenced by the different extracellular calcium 
concentrations with a trend similar to the PTH gene (F(2,73) = 13.97, P < 0.0001), with the 
mean value at 0.1 mM higher than the value at 1.2 mM calcium (t = −3.30, P = 0.0015) 
and 3.0 mM calcium (t = −5.23, P < 0.0001). Therefore, the regulation of the GATA3 gene 
expression by the extracellular calcium concentrations paralleled the one of the PTH gene 
(Fig. 2B).
Also for the expression of the GCM2 gene, statistically significant differences of the pre-
vious genes were observed (F(2,84) = 5.24, P = 0.0071). The value at 0.1 mM calcium was 
higher than the value at 1.2 mM (t = −2.50, P = 0.0145) and the value at 3.0 mM (t = −3.02, 
P = 0.0034) and this response paralleled what seen for the PTH and GATA3 genes (Fig. 2C).
The mean values of the MAFB gene were also different with respect to the 3 levels of 
calcium (F(2,85) = 6.02, P = 0.0036), where the mean value observed at 0.1 mM calcium was 
higher than the value at 1.2 mM (t = −2.50, P = 0.0145) and the value at 3.0 mM (t = −3.33, 
P = 0.0013). Therefore, the expression of the MAFB gene followed the same trend as the 
PTH, GATA3, and GCM2 genes with an inverse correlation with the extracellular calcium 
concentrations (Fig. 2D).
The results of the analysis of the effect on the parathyroid calcium response cascade 
showed that the CaSR gene expression was modulated by the 3 different extracellular cal-
cium concentrations (F(2,101)  =  4.58, P  =  0.0126), with the mean value of the CaSR gene 
Figure 1. The intracellular PTH and CaSR proteins were evaluated with immunofluores-
cence staining in adenoma parathyroid cells after 5 days in culture with growth medium 
and then transferred into glass slides and incubated for 24 h in DMEM medium containing 
1.2 mM calcium before the phase contrast analysis and the immunofluorescence staining. 
(A) Phase contrast image of an adenoma parathyroid primary culture (40× original magni-
fication). (B) Parathyroid cells stained for CaSR (in green) and counterstained for nuclei (in 
red). Observations with laser scanning confocal microscopy, objective 40× original magnifica-
tion. (C) Parathyroid cells stained for PTH (in green) and counterstained for nuclei (in red). 
Observations with laser scanning confocal microscopy, 40× original magnification.
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Table 3. Descriptive statistics (mean and standard deviation) of single parathyroid preparations
Gene Parathyroids 0.1 mM calcium 1.2 mM calcium 3.0 mM calcium
PTH 1 1.16 ± 0.33 0.79 ± 0.34 0.71 ± 0.16
2 1.93 ± 0.35 1.06 ± 0.38 0.99 ± 0.53
3 1.08 ± 0.23 0.71 ± 0.16 0.78 ± 0.16
4 1.97 ± 1.13  0.78 ± 0.26 1.12 ± 0.24
5 1.80 ± 0.97 1.03 ± 0.23 0.83 ± 0.25
6 20.51 ± 19.77 1.01 ± 0.23 0.22 ± 0.28
7 1.03 ± 0.28 0.93 ± 0.43 0.82 ± 0.09
8 1.26 ± 0.43 1.01 ± 0.13 0.81 ± 0.15
GATA3 1 1.49 ± 0.33 1.02 ± 0.21 0.73 ± 0.10
2 1.51 ± 0.11 1.01 ± 0.16 1.18 ± 0.21
3 1.31 ± 0.40 1.02 ± 0.19 0.95 ± 0.18
4 1.46 ± 0.64 1.02 ± 0.25 0.72 ± 0.12
5 2.27 ± 0.45 1.23 ± 0.70 0.49 ± 0.11
6 0.29 ± 0.05 0.24 ± 0.07 0.24 ± 0.03
7 1.20 ± 0.35 1.07 ± 0.52 0.91 ± 0.32
8 1.71 ± 1.13 1.01 ± 0.17 0.32 ± 0.14
GCM2 1 1.19 ± 0.41 1.01 ± 0.21 0.85 ± 0.12
2 1.56 ± 0.34 1.43 ± 0.14 1.36 ± 0.30
3 1.21 ± 0.40 1.03 ± 0.27 1.03 ± 0.25
4 10.56 ± 2.25 1.36 ± 0.86 0.05 ± 0.02
5 1.32 ± 0.52 1.04 ± 0.31 1.02 ± 0.29
6 0.87 ± 0.09 0.77 ± 0.09 0.73 ± 0.14
7 1.15 ± 0.35 0.97 ± 0.41 0.72 ± 0.18
8 1.70 ± 1.11 1.01 ± 0.17 0.83 ± 0.25
MAFB 1 2.14 ± 1.15 1.03 ± 0.27 0.97 ± 0.50
2 1.32 ± 0.54 1.01 ± 0.14 0.98 ± 0.16
3 1.62 ± 0.30 1.07 ± 0.40 0.34 ± 0.11
4 0.94 ± 0.17 1.05 ± 0.34 0.94 ± 0.16
5 0.53 ± 0.12 0.55 ± 0.10 0.54 ± 0.19
6 0.79 ± 0.12 0.77 ± 0.03 0.76 ± 0.04
7 0.88 ± 0.25 0.80 ± 0.33 0.78 ± 0.17
8 2.05 ± 1.38 1.01 ± 0.16 0.98 ± 0.47
CaSR 1 0.44 ± 0.12 0.33 ± 0.19 0.65 ± 0.37
2 1.16 ± 0.20 1.01 ± 0.15  0.95 ± 0.15
3 1.37 ± 0.40 1.01 ± 0.13 1.02 ± 0.22
4 3.24 ± 1.63 1.06 ± 0.38 2.44 ± 0.57
5 2.85 ± 0.36 1.15 ± 0.77 3.65 ± 0.54
6 1.22 ± 0.21  1.05 ± 0.30 0.90 ± 0.16
7 1.09 ± 0.26 0.95 ± 0.15 0.89 ± 0.08
8 1.46 ± 0.96 1.01 ± 0.11 0.65 ± 0.17
GNA11 1 3.45 ± 5.80 1.71 ± 1.81 3.01 ± 4.56
2 0.95 ± 0.15 1.01 ± 0.15 1.01 ± 0.22
3 1.47 ± 0.19 1.01 ± 0.13 1.16 ± 0.18
4 2.63 ± 0.60 1.02 ± 0.23 2.77 ± 0.48
5 3.21 ± 1.88 1.19 ± 0.83 5.00 ± 0.99
6 0.99 ± 0.21 1.07 ± 0.28 0.83 ± 0.26
7 1.03 ± 0.09 0.88 ± 0.07 0.57 ± 0.16
8 2.03 ± 1.47 1.31 ± 0.15 0.91 ± 0.36
AP2S1 1 1.40 ± 0.44 1.02 ± 0.75 1.22 ± 0.43
2 1.33 ± 0.96 1.39 ± 0.71 1.06 ± 0.59
3 1.02 ± 0.49 1.34 ± 0.64 1.56 ± 0.75
4 1.09 ± 0.71 0.99 ± 0.30 1.25 ± 0.46
5 1.08 ± 0.31 1.33 ± 0.59 1.34 ± 0.43
6 1.23 ± 0.39 1.07 ± 0.22 1.16 ± 0.38
7 1.18 ± 0.12 0.91 ± 0.19 1.53 ± 0.48
8 1.35 ± 0.53 1.13 ± 0.33 1.34 ± 0.61
doi: 10.1210/jendso/bvaa058 | Journal of the Endocrine Society | 9
observed at 0.1 mM calcium being higher than the one at physiological concentration of 
1.2 mM (t = 2.99, P = 0.0035). However, no differences were observed at 3.0 mM extracel-
lular calcium concentrations when compared to 1.2 mM calcium. The expression of the CaSR 
gene was modulated between 0.1 mM and 1.2 mM, with the same trend as the previously 
mentioned genes, but with a different behavior at high extracellular calcium concentrations 
(Fig. 2E).
Similarly, the GNA11 gene expression showed a response that paralleled the profile of 
the CaSR gene with a statistically significant difference at the 3 calcium levels (F(2,97) = 3.44, 
P = 0.036) and a mean value at 1.2 mM calcium, lower when compared to the mean value at 
0.1 mM (t = 2.62, P = 0.0101) (Fig. 2F).
Finally, for AP2S1 gene expression, no statistically significant differences were seen be-
tween the 3 tested calcium concentrations (F(2,101) = 0.33, P = 0.721). Unlike the expression 
of other genes analyzed, the AP2S1 gene was not modulated with the increase of the extra-
cellular calcium concentrations (Fig. 2G).
The expression of all the genes described in this paper was assessed in the cultured cells 
exposed to growth medium just before the challenge with various calcium concentrations in 
DMEM medium, and the results obtained were superimposable to what observed for each 
sample challenged with 1.2mM calcium (data not shown).
Discussion
Normal parathyroid cells have a very slow rate of proliferation, and in vitro primary cell 
cultures derived from human parathyroid cells are very difficult to obtain. Therefore, pri-
mary cultures of human parathyroid glands have mainly been derived from parathyroid 
Figure 2. Genes expression: PTH (A), GATA3 (B), GCM2 (C), MAFB (D), CaSR (E), GNA11 
(F), and AP2S1 (G) evaluated by RT-PCR in 8 different parathyroid cell cultures. messenger 
ribonucleic acid expression was evaluated in 3 calcium concentrations (0.1 mM, 1.2 mM, and 
3.0 mM calcium) for 1 h. Data are normalized against ACTB messenger ribonucleic acid.
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adenomas and hyperplastic glands coming from patients with hyperparathyroidism, which 
were shown to have a higher proliferative activity compared to normal glands [26,31]. 
However, the culture of human parathyroid cells presents several difficulties. There is an 
overgrowth of fibroblasts, which becomes evident after 8 to 10 days of culture, together 
with a slow in vitro proliferation exhibited by these cells, and by a decreased expression of 
the CaSR at messenger ribonucleic and protein levels. This behavior causes a decreased 
sensitivity of the CaSR receptor to the extracellular calcium. Moreover, a reduced calcium 
sensing function and calcium receptor expression, seen in adenomatous and hyperplastic 
cells, have been attributed to various degrees of functional dedifferentiation [32].
Besides all the limitations that pathologic human parathyroid tissues present, cells cul-
tured from parathyroid adenomatous and hyperplastic tissues represent an accepted model 
for in vitro parathyroid physiopathology investigations.
Mouse embryology has made it possible to characterize the genetic control of parathy-
roid development. The embryonic formation of the parathyroid glands, together with the 
thymus, includes a complex transcriptional network that involves HOXA3, PAX1/PAX9, 
EYA1, TBX1, SOX3, and SIX1/SIX4 genes, able to control the formation of the parathy-
roid/thymus common primordium [40,41]. After the generation of the third pouch, the par-
athyroid domain can be distinguished by the expression of the GCM2 gene, fundamental 
for parathyroid survival and differentiation. In mice that lack HOXA3, PAX1/PAX9, EYA1, 
and SIX1/SIX4 genes, parathyroid glands are either absent or hypoplastic. These genes are 
mediated by the effect of the GCM2 gene, whose absent expression causes apoptosis of the 
parathyroid chief cells [42]. The parathyroid developing cascade includes also GATA3 and 
MAFB genes [5,27]. Interestingly, the 3 genes, GCM2, GATA3, and MAFB, maintain an ex-
pression postnatally when they control the expression of the PTH gene [3,4].
In humans, congenital disorders were essential for understanding the role of the genes 
important in mouse parathyroid development, as mutations of the genes involved in mouse 
parathyroid morphogenesis can translate into hypoparathyroidism or hyperparathyroidism 
syndromes [10,11,15,16,43]. However, the role of developmental transcription factors in 
adult parathyroid physiology and pathophysiology is still unclear.
To understand the interactions of GATA3, GCM2, and MAFB genes with the calcium 
response machinery, primary cultures obtained from human parathyroid adenomas were 
utilized to evaluate the effect of different extracellular calcium concentrations on the ex-
pression of both morphogenesis and functional genes. The results obtained show for the 
first time an in vitro role of extracellular calcium in controlling the expression of GATA3, 
GCM2, and MAFB genes in a parallel fashion to the response of the PTH gene. What would 
be the significance of the increased GATA3, GCM2, and MAFB genes expression in the par-
athyroid cells at low extracellular calcium concentrations? A potential explanation for this 
finding can be read in the cooperation of the three transcription factors, known to activate 
the PTH gene [3,4], with low calcium concentrations. The mirror condition would be one 
of high calcium concentrations where the 3 transcription factors are inhibited by calcium 
with a potentiation of calcium inhibitory effect on PTH secretion. This can certainly lead to 
future pharmacological interventions of great interest for both hyper- and hypo-functional 
parathyroid conditions.
An interesting finding of the experiments carried out in this study is the increase in 
the expression of the CaSR and GNA11 genes at low extracellular calcium concentrations, 
without a response of the AP2S1 gene, the other known component of the parathyroid cal-
cium response cascade. Regarding the potential transactivation of the CaSR gene by extra-
cellular calcium, the results are controversial. Theoretically, a control exerted by calcium 
on CASR gene expression could interfere with the function of the calciostat for the receptor 
and, therefore, disturb the calcium homeostasis. The original studies, which excluded an 
effect of calcium in controlling the CaSR gene, were conducted in rats infused with calcium 
[44]. However, in those pioneering studies, the lowest calcium concentration was 0.7 mM. 
This concentration cannot exclude the possibility that a rescue function of increased CaSR 
gene expression could exist at very low extracellular calcium concentrations, in order to 
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counteract an excessive secretion of PTH. This interpretation could easily encompass the 
stimulating effect that the higher GCM2 gene expression, observed at low extracellular 
calcium concentrations, could exert on the expression of the CaSR gene through P1 and 
P2 promoters [19]. The different response to extracellular calcium observed for the other 2 
genes of the calcium response cascade, GNA11 and AP2S1 genes, are not easily interpret-
able. The different physical positions of the encoded proteins—one, GNA11, close to the cel-
lular membrane and the other, AP2S1, intracellular—could explain the lack of response of 
the AP2S1 gene to extracellular calcium concentrations.
In conclusion, the present in vitro study has shown for the first time that genes involved 
either in the development or in the function of the parathyroid glands are themselves 
controlled by extracellular calcium concentrations. These findings prompt new avenues of 
investigation that could unravel still unrecognized molecular mechanisms that control the 
parathyroid chief cells in physiological and pathological conditions.
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